Compare Sezzle Inc (SEZL) vs Summit Therapeutics Inc (SMMT) Price & Performance

Sezzle Inc. (SEZL) trades at $171.76, down 1.67% today, with a bullish technical signal from moving averages and a neutral RSI near 50. The stock shows strong fundamental momentum, with Q1 2026 EPS of $1.43 beating estimates of $1.24, and robust profitability metrics including a 30.83% net income margin and 91.95% ROE. Recent news highlights subscriber growth of 48.4% year-over-year and product expansions, supporting the positive sentiment.

Outlook remains favorable due to consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 41) and competitive pressures in the BNPL sector. Analyst consensus is a Moderate Buy with a $162 price target, suggesting potential downside from current levels, though the high target of $190 indicates upside if growth persists.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.